Key Segmentation
By Therapy
-
Targeted Therapy
-
Supportive Therapy
-
Pipeline Therapy
By Type
-
ATTR with Polyneuropathy (ATTR-PN)
-
ATTR with Cardiomyopathy (ATTR-CM
By Disease
-
Hereditary Transthyretin Amyloidosis
-
Wild Type Amyloidosis
By Distribution Channel
-
Hospital Pharmacies
-
Specialty Pharmacies
-
Retail Pharmacies
-
Online Pharmacies
Regional Coverage:
North America
-
United States
-
Canada
Europe
-
Germany
-
United Kingdom
-
France
-
Italy
-
Spain
-
Russia
-
Poland
-
Rest of Europe
Asia Pacific
-
China
-
India
-
Japan
-
South Korea
-
Australia
-
ASEAN Countries
-
Rest of Asia Pacific
Middle East & Africa
-
UAE
-
Saudi Arabia
-
Qatar
-
South Africa
-
Rest of Middle East & Africa
Latin America
-
Brazil
-
Argentina
-
Mexico
-
Colombia
-
Rest of Latin America
Available Customization
With the given market data, SNS Insider offers customization as per the company’s specific needs. The following customization options are available for the report:
-
Detailed Volume Analysis
-
Criss-Cross segment analysis (e.g. Product X Application)
-
Competitive Product Benchmarking
-
Geographic Analysis
-
Additional countries in any of the regions
-
Customized Data Representation
-
Detailed analysis and profiling of additional market players
Frequently Asked Questions
North America dominated the Transthyretin Amyloidosis Treatment Market in 2025 with approximately 46% market share, while Asia Pacific is the fastest-growing region.
The increasing incidence of transthyretin amyloidosis, combined with advances in gene-silencing therapies and improved diagnostic techniques that catch more cases earlier.
The Transthyretin Amyloidosis Treatment Market was valued at USD 8.95 Billion in 2025.